Radioiodtherapie und ¹³¹I-Ganzkörperszintigraphie zwischen evidentia^{[ 1 ]} und evidence^{[ 2 ]}

 

¹ lat. Augenscheinlichkeit

² engl. Beweis

• Literatur

• 1 Bachelot A, Leboulleux S, Baudin E. et al. Neck recurrence from thyroid carcinoma: serum thyro- globulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 2005; 62: 376-379.
• 2 Bal C, PadhyA K, Jana S. et al. Prospective randomised clinical trial to evaluate the optimal dose of ¹³¹I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77: 1077-1081.
• 3 Biermann M, Pixberg MK, Schuck A. et al. Multicenter Study Differentiated Thyroid Carcinoma (MSDS): diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003; 42: 244-250.
• 4 Biermann M, Pixberg MK, Dörr U. et al. Impact of clinical practice guidelines on radioiodine therapy for differentiated thyroid carcinoma. Nuklearmedizin 2005; 44: 229-237.
• 5 Biermann M, Schober O. Should high hTg levels in the absence of iodine uptake be treated?. Eur J Nucl Med Mol Imaging 2003; 30: 160-163.
• 6 Carril JM, Quirce R, Serrano J. et al. Total-body scintigraphy with thallium-201 andiodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 1997; 38: 686-692.
• 7 Chow SM, Law SC, Chan JK. et al. Papillary microcarcinoma of the thyroid - prognostic significance oflymph node metastasis andmultifocality. Cancer 2003; 98: 31-40.
• 8 Cooper DS, Specker B, Ho M. et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8: 737-744.
• 9 Cooper DS, Doherty GM, Haugen BR. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1-33.
• 10 DeGroot LJ, Kaplan EL, McCormick M. et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
• 11 Deutsche Krebsgesellschaft: Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Chirurgie. Maligne Schilddrüsentumoren. 2006 www.uni-duessel dorf.de/AWMF.
• 12 Dietlein M, Schober O, Schicha H. über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? überlegungen zur ablativen Radio- iodtherapie. Nuklearmedizin 2004; 43: 107-114.
• 13 Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A. Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidecto- my combined with radioiodine ablation enough?. Nucl Med Commun 2005; 26: 3-8.
• 14 Dietlein M, Dederichs B, Kobe C. et al. Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 2006; 45: 21-34.
• 15 Dietlein M, Dressler J, Eschner W. et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 213-219.
• 16 Dietlein M, Dressler J, Eschner W. et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 206-212.
• 17 Dietlein M, Dressler J, Grünwald F. et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 2007; 46: 220-223.
• 18 Dietlein M, Dressler J, Eschner W. et al. Procedure guideline for thyroid scintigraphy (version 3). Nuklearmedizin 2007; 46: 203-205.
• 19 Dietlein M, Dressler J, Eschner W. et al. Procedure guideline for radioiodine test (version 3). Nuklearmedizin 2007; 46: 198-202.
• 20 Dralle H, Sekulla C. Morbidität nach subtotaler und totaler Thyreoidektomie beim Morbus Basedow: Entscheidungsgrundlage für Operationsindikation und Resektionsausmaß. Z ärztl Fortbild Qual Gesundh 2004; 98 (Suppl V) 45-53.
• 21 Eschmann SM, Reischl G, Bilger K. et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodi- ne-124 and PET. Eur J Nucl Med Mol Imaging 2002; 29: 760-767.
• 22 Franzius C, Dietlein M, Biermann M. et al. Procedure guideline for radioiodine therapy and ¹³¹I whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007; 46: 224-231.
• 23 Freudenberg L, Jentzen W, Görges R. et al. 124I-po- sitron emission tomography dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007; 46: 121-128.
• 24 Görges R, Brandt-Mainz K, Freudenberg L. et al. Kontinuierliche Sensitivitätssteigerung in der Schilddrüsenkarzinom-Nachsorge im Verlauf dreier Thyreoglobulin-IMA Generationen. Nuklearmedizin 2003; 42: 157-166.
• 25 Gotthardt M, Stübinger M, Pansegrau J. et al. Decrease of 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s. Nuklearmedizin 2006; 45: 122-125.
• 26 Haenscheid H, Lassmann M, Luster M. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47: 648-654.
• 27 Lee TH, Torchiana DF, Lock JE. Is zero the ideal death rate?. N Engl J Med 2007; 357: 111-113.
• 28 Lerch H, Schober O, Kuwert T. et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
• 29 Lassmann M, Luster M, Hanscheid H. et al. Impact of ¹³¹I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45: 619-625.
• 30 Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103: 2269-2273.
• 31 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical andmedical therapy on papillary and fol- licularthyroidcancer. AmJMed 1994; 97: 418-428.
• 32 Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 1994; 106: 151-170.
• 33 McGriff NJ, Csako G, Gourgiotis L. et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34: 554-564.
• 34 Nakada K, Ishibashi T, Takei T. et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?. J Nucl Med 2005; 46: 261-266.
• 35 Pacini F, Ladenson PW, Schlumberger M. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-932.
• 36 Pacini F, Schlumberger M, Dralle H. et al. and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur JEndocrinol 2006; 154: 787-803.
• 37 Pelizzo MR, Boschin IM, Toniato A. et al. Natural history, diagnosis, treatment and outcome of pa- pillarythyroidmicrocarcinoma(PTMC): amono- institutional 12-year experience. Nucl Med Commun 2004; 25: 547-552.
• 38 Richtlinie Strahlenschutz in der Medizin 2002. 5. Auflage mit ausführlichem Erläuterungsteil. von Kemmer W, und Michalczak H. Berlin: H. Hoffmann; 2003
• 39 Riemann B, Schober O. Das kleine Schilddrüsenkarzinom. Nuklearmedizin 2007; 46: 113-114.
• 40 Robbins RJ, Chon JT, Fleisher M. et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. J Clin Endocrinol Metab 2002; 87: 3242-3247.
• 41 Rubino C, de Vathaire F, Dottorini ME. et al. Second primary malignancy in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
• 42 Samaan NA, Schultz PN, Hickey RC. et al. The results of various modalities of treatment of well differentiated thyroid cancinomas: aretrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-720.
• 43 Sawka AM, Thephamongkhol K, Brouwers M. et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. JClin Endocrinol Metab 2004; 89: 3668-3676.
• 44 Schlumberger M, Mancusi F, Baudin E. et al. ¹³¹I therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273-276.
• 45 Schwab R, Wieler H, Birtel S. et al. Confronting the practice of surgery on differentiated thyroid cancer with current guidelines in Germany. Nuklearmedizin 2005; 44: 185-191.
• 46 Sgouros G, Kolbert KS, Sheikh A. et al. Patient- specific dosimetry for ¹³¹I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-1372.
• 47 Smallridge RC, Meek SE, Morgan MA. et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 82-87.
• 48 Strahlenschutzkommission. Notwendigkeit der stationären Durchführung der Ganzkörperszinti- graphie mit Iod-131 beim Schilddrüsenkarzinom. Empfehlung der Strahlenschutzkommission. Verabschiedet in der 190. Sitzung der SSKam22./23. April 2004 Bundesanzeiger Nr. 158 vom 24.08.2004. Köln: Bundesanzeiger 2004
• 49 Strahlenschutzverordnung. Textausgabe mit Anmerkungen. von Witt E, Jäger E, Kasper L. 12. Aufl., Köln, Berlin: Carl Heymanns; 2002
• 50 Taylor T, Specker B, Robbins J. et al. Outcome after treatment of high-risk papillary and non-Hu- erthle-cell follicular thyroid carcinoma. Ann In- ternMed 1998; 129: 622-627.
• 51 Van Tol KM, Jager PL, de Vries EG. et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003; 148: 589-596.
• 52 Zöphel K, Wunderlich G, Kotzerke J. A highly sensitive thyroglobulin assay has superior diagnostic sensitivity for recurrence of differentiated thyroid cancer in patients undergoing TSH suppression. J Nucl Med 2006; 47: 552-553.